[ad_1]
New York, August 30: Prior exposure to SARS-CoV-2, the virus that causes Covid-19, does not guarantee a high level of antibodies or immunity to reinfection as previously thought, according to a study highlighting the need for get vaccinated against the deadly infectious disease.
The study, led by researchers at Northwestern University in the United States, shows that two months after the second Pfizer / Moderna vaccination, the antibody response decreases by 20% in adults with previous cases of Covid-19.
He added that prior exposure to SARS-CoV-2 does not guarantee a robust antibody response to the first dose of vaccine. This directly contradicts the assumption that contracting Covid will naturally make a person immune to reinfection. The findings, published in the journal Scientific Reports, further support vaccination (and two doses), even for people who have already contracted the virus. Scientists are developing artificial antibodies, paving the way for non-hormonal contraception.
“Many people and physicians assume that any previous exposure to SARS-CoV-2 will confer immunity to reinfection. Based on this logic, some people who have been exposed do not think they need to be vaccinated. Or if they get the vaccine, they think they only need the first dose of the two-dose Pfizer / Moderna vaccine, ”said Thomas McDade, professor of anthropology at the Weinberg College of Arts and Sciences and fellow of the faculty at the University’s Institute for Policy. Research.
“Our study shows that prior exposure to SARS-CoV-2 does not guarantee a high level of antibodies, nor a robust antibody response to the first dose of vaccine. For people who have had mild or asymptomatic infections, their antibody response to vaccination is essentially the same as for people who have never been exposed before, ”he added.
For the study, the team tested blood samples from adults who had contracted Covid to measure how long the immune benefits of the Pfizer and Moderna vaccines last and how well they protect against the new variants.
When the team tested blood samples from participants taken about three weeks after their second dose of vaccine, the average level of inhibition was 98%, indicating a very high level of neutralizing antibodies.
Scientists tested the emerging variants B.1.1351 (Beta), B.1.1.7 (Alpha) and P.1 (Gamma) and found that the level of inhibition of viral variants was significantly lower, ranging from 67% at 92%. Genetic Risk Scores May Help Accurate Diagnosis of Epilepsy: Study.
They also found that the antibody response decreased by about 20% after two months and that the antibody response to vaccination varied depending on the history of infection.
Additionally, people with clinically confirmed cases of Covid-19 and multiple symptoms also showed a higher level of response than those who tested positive but had mild symptoms or were asymptomatic.
(The above story first appeared on LatestLY on August 30, 2021 at 7:23 PM IST. For more info and updates on Politics, World, Sports, Entertainment, and Fashion life, connect to our website Latestly.com).
[ad_2]
Source link
